Go to the list of all blogs
Sergey Savastiouk's Avatar
published in Blogs
Oct 28, 2026
TickeronGET DAILY SIGNALS
Cingulate (CING) Shares Advance +14.7% in 30 Days as NDA Resubmission Nears

Cingulate (CING) Shares Advance +14.7% in 30 Days as NDA Resubmission Nears

Key Takeaways

  • Cingulate (CING) shares advanced roughly 14.7% over the trailing 30 days, rising from about $4.82 to $5.53.
  • The stock pulled back into mid-October before staging a sharp late-month rebound, highlighting its elevated volatility.
  • Over the trailing quarter, CING is up roughly 22%, supported by progress toward a New Drug Application (NDA) resubmission for lead ADHD candidate CTx-1301.
  • The FDA's Complete Response Letter centered on chemistry, manufacturing, and controls (CMC) items rather than clinical safety or efficacy.
  • A strengthened balance sheet, with a cash runway into mid-2027, remains a central focus for investors.

Cingulate (CING) Company Overview and Market Position

Cingulate Inc. is a clinical-stage biopharmaceutical company headquartered in Kansas City, Kansas, focused on developing next-generation treatments for attention-deficit/hyperactivity disorder (ADHD) and other central nervous system conditions. Its core technology is the proprietary Precision Timed Release (PTR) drug delivery platform, which is designed to release medication in controlled pulses at specific times throughout the day.

The company's lead asset is CTx-1301 (dexmethylphenidate hydrochloride), a once-daily, multi-core tablet intended to provide rapid onset and sustained symptom control across a patient's active day. Because CING is pre-revenue, its valuation is driven primarily by regulatory progress, intellectual property, financing, and commercial-readiness milestones rather than current sales or earnings. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.

Cingulate (CING) Stock Price Performance: Last 30 Days vs. Quarter

Over the trailing 30 days, CING shares climbed about 14.7%, moving from a closing level near $4.82 in late September to roughly $5.53. The move was not a straight line: the stock declined through early-to-mid October, touching an intraday low around $4.12 before rebounding sharply in the final sessions of the period.

The quarterly picture is stronger but equally volatile. Over the last three months, the stock has gained roughly 22%, rising from about $4.53 to $5.53. The quarter included a late-August peak near $5.87, a subsequent retracement, and a late-October recovery. This pattern reflects the binary, sentiment-driven nature typical of clinical-stage biotechnology equities awaiting regulatory decisions. From what I see, these swings underscore the importance of monitoring key catalysts closely.

What Drove CING Stock Price in the Last 30 Days

The 30-day period was defined by a pullback into mid-October followed by a pronounced late-month rebound. No single disclosed announcement coincided with the recovery's final leg, but the backdrop included several company-specific fundamentals that shaped investor positioning.

Cingulate continues to work with its manufacturing partner to complete the CMC work requested in the FDA's Complete Response Letter for CTx-1301, with the goal of resubmitting the NDA. The letter did not raise clinical safety or efficacy concerns, which has kept the regulatory story focused on execution rather than the drug's effectiveness. The company has also reported a cash position sufficient to fund operations into mid-2027, reducing near-term financing overhang for some investors. These factors, combined with typical small-cap biotech volatility, contributed to the stock's recovery from its October lows.

What Drove CING Stock Performance Over the Last Quarter

The quarter's broader narrative centers on Cingulate's regulatory and operational progress. In June, the company received a Complete Response Letter from the FDA for CTx-1301 that requested additional CMC information while identifying no clinical safety or efficacy concerns. The company subsequently reported second-quarter results and outlined its plan to resubmit the NDA.

Several supporting developments reinforced the investment case during the quarter. Cingulate received its first U.S. patent for CTx-1301, extending exclusivity into late 2042. The company was added to the Russell 3000E Index, potentially broadening institutional visibility. Peer-reviewed and Phase 3 data publications highlighted CTx-1301's differentiated pharmacokinetic profile, and a distribution agreement with Prasco advanced commercial-readiness infrastructure ahead of a potential launch. These milestones, layered on a strengthened balance sheet, shaped the stock's net advance over the period. I'm watching this closely as execution on the resubmission timeline could be pivotal.

CING Stock Forecast Drivers: What Investors Should Watch Next

Looking ahead, the primary catalyst for Cingulate remains the CTx-1301 NDA resubmission and the FDA's subsequent response. Investors will also monitor the company's completion of CMC work with its manufacturing partner, updates on commercial-readiness activities, and any additional intellectual-property developments. Balance-sheet management and the pace of cash utilization into mid-2027 are also important considerations, as is broader sentiment toward clinical-stage biotech equities. As with any pre-revenue drug developer, outcomes remain uncertain, and regulatory, financing, and execution risks should be weighed carefully.

Using AI Tools to Analyze Biotech Opportunities

In my view, tools like Tickeron’s AI Trading Bots can provide useful context when evaluating volatile names like CING. I often review their performance metrics alongside traditional analysis to understand how algorithmic strategies are positioned in the sector. This helps highlight potential patterns without replacing fundamental research.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Related Ticker: CING

Contributor

Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.


CING's RSI Oscillator ascending out of oversold territory

The RSI Oscillator for CING moved out of oversold territory on November 17, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 38 similar instances when the indicator left oversold territory. In 35 of the 38 cases the stock moved higher. This puts the odds of a move higher at 90%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 56 of 66 cases where CING's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 85%.

The Momentum Indicator moved above the 0 level on November 17, 2026. You may want to consider a long position or call options on CING as a result. In 77 of 87 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 89%.

Following a +4.27% 3-day Advance, the price is estimated to grow further. Considering data from situations where CING advanced for three days, in 193 of 228 cases, the price rose further within the following month. The odds of a continued upward trend are 85%.

CING may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Bearish Trend Analysis

The Moving Average Convergence Divergence Histogram (MACD) for CING turned negative on November 04, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 48 similar instances when the indicator turned negative. In 41 of the 48 cases the stock turned lower in the days that followed. This puts the odds of success at 85%.

CING moved below its 50-day moving average on November 03, 2026 date and that indicates a change from an upward trend to a downward trend.

The 10-day moving average for CING crossed bearishly below the 50-day moving average on November 06, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 12 of 15 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 80%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where CING declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.

The Aroon Indicator for CING entered a downward trend on October 26, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron Price Growth Rating for this company is 63 (best 1 - 100 worst), indicating steady price growth. CING’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Valuation Rating of 64 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.640) is normal, around the industry mean (3.592). P/E Ratio (-1.197) is within average values for comparable stocks, (-1.190). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (131.305) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (442.120).

The Tickeron PE Growth Rating for this company is 100 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CING’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

Notable companies

The most notable companies in this group are Moderna (NASDAQ:MRNA), Regeneron Pharmaceuticals (NASDAQ:REGN), Incyte Corp (NASDAQ:INCY), Exelixis (NASDAQ:EXEL), Arrowhead Pharmaceuticals (NASDAQ:ARWR), Sarepta Therapeutics (NASDAQ:SRPT), Novavax (NASDAQ:NVAX), Nektar Therapeutics (NASDAQ:NKTR), Inovio Pharmaceuticals (NASDAQ:INO), Cel-Sci Corp (ASE:CVM).

Industry description

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

Market Cap

The average market capitalization across the Biotechnology Industry is 2.24B. The market cap for tickers in the group ranges from 58 to 138.67B. VRTX holds the highest valuation in this group at 138.67B. The lowest valued company is SEELQ at 58.

High and low price notable news

The average weekly price growth across all stocks in the Biotechnology Industry was -11%. For the same Industry, the average monthly price growth was -10%, and the average quarterly price growth was -24%. SLS experienced the highest price growth at 129%, while CUE experienced the biggest fall at -85%.

Volume

The average weekly volume growth across all stocks in the Biotechnology Industry was 8%. For the same stocks of the Industry, the average monthly volume growth was 10% and the average quarterly volume growth was -15%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 50
P/E Growth Rating: 44
Price Growth Rating: 67
SMR Rating: 93
Profit Risk Rating: 93
Seasonality Score: -3 (-100 ... +100)
Real Time Patterns 3
View a ticker or compare two or three
Interact to see
Advertisement
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

Industry Biotechnology

Industry
N/A
Address
1901 West 47th Place
Phone
+1 913 942-2300
Employees
14
Web
https://www.cingulate.com
Interact to see
Advertisement
UNH dropped -7.80% to $359.29 from Tuesday's $389.68 close, extending a two-session decline to roughly -13% and touching its lowest level in about seven weeks; the move occurred during regular market hours. The selloff accelerated on the CMS "CRUSH" proposal unveiled Nov. 16, which would extrapolate Medicare Advantage risk-adjustment audit findings from samples across entire contracts back to payment year 2018 and drop the fee-for-service adjuster; CMS estimates roughly $9 billion in industry clawbacks per payment year, and UnitedHealth, the largest MA insurer, has not sized its exposure.
SAP's U.S. shares fell from Monday's close of $233.83 to $221.99 by late Tuesday morning in New York, a -5.06% decline recorded during regular trading hours. The company-specific trigger was the announced exit of Chief Customer Officer Thomas Saueressig, an executive board member since 2019, who will leave at the end of March 2027 to become CEO of IONOS; the disclosure came before the U.S. open.
Different growth engines: MRVL is riding accelerating AI data-center demand for custom chips and networking, while QCOM remains heavily tied to a soft smartphone market. Momentum contrast: Marvell's data-center revenue guidance has strengthened, whereas Qualcomm's near-term outlook has been pressured by memory-supply constraints and shrinking handset volumes.
TMC fell from Monday's $2.11 close to $1.96 by 10:10 a.m. ET, a -7.11% decline that occurred entirely in the regular session after an early premarket gain faded. No verified news or fundamental catalyst found for the drop; the move is likely technical, extending the post-Q3 unwind that followed NOAA pushing its certification decision to mid-December, with the stock averaging a 4.0% daily swing and logging 11 sessions of 7%-or-larger moves in the last 60.
IonQ slid from Monday's close of $26.45 to $24.73 on Tuesday, a -6.50% move that unfolded during regular trading hours after modest premarket gains faded. The decline was sector-driven rather than company-specific: quantum and AI-adjacent speculative names extended a multi-session liquidation ahead of Nvidia's quarterly report, with unease over Nvidia's abrupt CEO transition keeping risk appetite weak.